Quantitative analysis of keratin 18 in the urine of patients with bladder cancer

W. C. Baker, Ralph W deVere White, P. V. Rossitto, B. H. Min, Robert Cardiff

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

The level of urinary keratin was compared in patients with and without bladder cancer using the newly developed IRMAK-18. Patients with bladder cancer had higher levels of keratin (74.6 ± 146.9) than normals (2.5 ± 4.7). When the upper limit of normal was set at keratin <20 ng./ml., the test was highly specific (98%) for bladder cancer but had a sensitivity of only 46%. Adjusting to keratin <10 ng./ml. increased the sensitivity to 57% but decreased the specificity to 91%. Elevated keratins were associated with stage and grade, aneuploidy and disease history. The IRMAK-18 assay for keratin may be useful for monitoring the clinical progress of some patients.

Original languageEnglish (US)
Pages (from-to)436-439
Number of pages4
JournalJournal of Urology
Volume140
Issue number2
StatePublished - 1988

Fingerprint

Keratin-18
Keratins
Urinary Bladder Neoplasms
Urine
Aneuploidy

ASJC Scopus subject areas

  • Urology

Cite this

Quantitative analysis of keratin 18 in the urine of patients with bladder cancer. / Baker, W. C.; deVere White, Ralph W; Rossitto, P. V.; Min, B. H.; Cardiff, Robert.

In: Journal of Urology, Vol. 140, No. 2, 1988, p. 436-439.

Research output: Contribution to journalArticle

@article{731e9d7b333241a6ac79616ace083abf,
title = "Quantitative analysis of keratin 18 in the urine of patients with bladder cancer",
abstract = "The level of urinary keratin was compared in patients with and without bladder cancer using the newly developed IRMAK-18. Patients with bladder cancer had higher levels of keratin (74.6 ± 146.9) than normals (2.5 ± 4.7). When the upper limit of normal was set at keratin <20 ng./ml., the test was highly specific (98{\%}) for bladder cancer but had a sensitivity of only 46{\%}. Adjusting to keratin <10 ng./ml. increased the sensitivity to 57{\%} but decreased the specificity to 91{\%}. Elevated keratins were associated with stage and grade, aneuploidy and disease history. The IRMAK-18 assay for keratin may be useful for monitoring the clinical progress of some patients.",
author = "Baker, {W. C.} and {deVere White}, {Ralph W} and Rossitto, {P. V.} and Min, {B. H.} and Robert Cardiff",
year = "1988",
language = "English (US)",
volume = "140",
pages = "436--439",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Quantitative analysis of keratin 18 in the urine of patients with bladder cancer

AU - Baker, W. C.

AU - deVere White, Ralph W

AU - Rossitto, P. V.

AU - Min, B. H.

AU - Cardiff, Robert

PY - 1988

Y1 - 1988

N2 - The level of urinary keratin was compared in patients with and without bladder cancer using the newly developed IRMAK-18. Patients with bladder cancer had higher levels of keratin (74.6 ± 146.9) than normals (2.5 ± 4.7). When the upper limit of normal was set at keratin <20 ng./ml., the test was highly specific (98%) for bladder cancer but had a sensitivity of only 46%. Adjusting to keratin <10 ng./ml. increased the sensitivity to 57% but decreased the specificity to 91%. Elevated keratins were associated with stage and grade, aneuploidy and disease history. The IRMAK-18 assay for keratin may be useful for monitoring the clinical progress of some patients.

AB - The level of urinary keratin was compared in patients with and without bladder cancer using the newly developed IRMAK-18. Patients with bladder cancer had higher levels of keratin (74.6 ± 146.9) than normals (2.5 ± 4.7). When the upper limit of normal was set at keratin <20 ng./ml., the test was highly specific (98%) for bladder cancer but had a sensitivity of only 46%. Adjusting to keratin <10 ng./ml. increased the sensitivity to 57% but decreased the specificity to 91%. Elevated keratins were associated with stage and grade, aneuploidy and disease history. The IRMAK-18 assay for keratin may be useful for monitoring the clinical progress of some patients.

UR - http://www.scopus.com/inward/record.url?scp=0023801713&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023801713&partnerID=8YFLogxK

M3 - Article

C2 - 2456406

AN - SCOPUS:0023801713

VL - 140

SP - 436

EP - 439

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 2

ER -